Cellular tumor antigen p53

Details

Name
Cellular tumor antigen p53
Synonyms
  • Antigen NY-CO-13
  • P53
  • Phosphoprotein p53
  • Tumor suppressor p53
Gene Name
TP53
Organism
Humans
Amino acid sequence
>lcl|BSEQ0006595|Cellular tumor antigen p53
MEEPQSDPSVEPPLSQETFSDLWKLLPENNVLSPLPSQAMDDLMLSPDDIEQWFTEDPGP
DEAPRMPEAAPPVAPAPAAPTPAAPAPAPSWPLSSSVPSQKTYQGSYGFRLGFLHSGTAK
SVTCTYSPALNKMFCQLAKTCPVQLWVDSTPPPGTRVRAMAIYKQSQHMTEVVRRCPHHE
RCSDSDGLAPPQHLIRVEGNLRVEYLDDRNTFRHSVVVPYEPPEVGSDCTTIHYNYMCNS
SCMGGMNRRPILTIITLEDSSGNLLGRNSFEVRVCACPGRDRRTEEENLRKKGEPHHELP
PGSTKRALPNNTSSSPQPKKKPLDGEYFTLQIRGRERFEMFRELNEALELKDAQAGKEPG
GSRAHSSHLKSKKGQSTSRHKKLMFKTEGPDSD
Number of residues
393
Molecular Weight
43652.79
Theoretical pI
6.78
GO Classification
Functions
ATP binding / chaperone binding / chromatin binding / copper ion binding / core promoter sequence-specific DNA binding / damaged DNA binding / DNA binding / double-stranded DNA binding / enzyme binding / histone acetyltransferase binding / histone deacetylase regulator activity / identical protein binding / p53 binding / protease binding / protein heterodimerization activity / protein kinase binding / protein N-terminus binding / protein phosphatase 2A binding / protein phosphatase binding / protein self-association / receptor tyrosine kinase binding / RNA polymerase II core promoter sequence-specific DNA binding / RNA polymerase II transcription factor activity, sequence-specific DNA binding / RNA polymerase II transcription factor binding / sequence-specific DNA binding / transcription factor activity, sequence-specific DNA binding / transcription factor binding / transcription regulatory region DNA binding / transcriptional activator activity, RNA polymerase II core promoter proximal region sequence-specific binding / transcriptional activator activity, RNA polymerase II transcription regulatory region sequence-specific binding / ubiquitin protein ligase binding / zinc ion binding
Processes
apoptotic process / B cell lineage commitment / base-excision repair / blood coagulation / cell aging / cell cycle arrest / cell differentiation / cell proliferation / cellular protein localization / cellular response to DNA damage stimulus / cellular response to drug / cellular response to glucose starvation / cellular response to hypoxia / cellular response to ionizing radiation / cellular response to UV / cellular response to UV-C / cerebellum development / chromatin assembly / chromosome breakage / circadian behavior / determination of adult lifespan / DNA damage response, signal transduction by p53 class mediator / DNA damage response, signal transduction by p53 class mediator resulting in cell cycle arrest / DNA damage response, signal transduction by p53 class mediator resulting in transcription of p21 class mediator / DNA repair / DNA strand renaturation / double-strand break repair / embryonic organ development / entrainment of circadian clock by photoperiod / ER overload response / gastrulation / gene expression / in utero embryonic development / intrinsic apoptotic signaling pathway / intrinsic apoptotic signaling pathway by p53 class mediator / intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediator / intrinsic apoptotic signaling pathway in response to hypoxia / mitochondrial DNA repair / mitotic cell cycle arrest / mitotic G1 DNA damage checkpoint / multicellular organism growth / multicellular organismal development / necroptotic process / negative regulation of apoptotic process / negative regulation of cell growth / negative regulation of cell proliferation / negative regulation of DNA replication / negative regulation of fibroblast proliferation / negative regulation of glucose catabolic process to lactate via pyruvate / negative regulation of helicase activity / negative regulation of macromitophagy / negative regulation of neuroblast proliferation / negative regulation of proteolysis / negative regulation of reactive oxygen species metabolic process / negative regulation of transcription from RNA polymerase II promoter / negative regulation of transcription, DNA-templated / negative regulation of transforming growth factor beta receptor signaling pathway / neuron apoptotic process / Notch signaling pathway / nucleotide-excision repair / oligodendrocyte apoptotic process / oxidative stress-induced premature senescence / positive regulation of apoptotic process / positive regulation of cardiac muscle cell apoptotic process / positive regulation of cell cycle arrest / positive regulation of execution phase of apoptosis / positive regulation of gene expression / positive regulation of histone deacetylation / positive regulation of intrinsic apoptotic signaling pathway / positive regulation of mitochondrial membrane permeability / positive regulation of neuron apoptotic process / positive regulation of peptidyl-tyrosine phosphorylation / positive regulation of protein insertion into mitochondrial membrane involved in apoptotic signaling pathway / positive regulation of protein oligomerization / positive regulation of reactive oxygen species metabolic process / positive regulation of release of cytochrome c from mitochondria / positive regulation of thymocyte apoptotic process / positive regulation of transcription from RNA polymerase II promoter / positive regulation of transcription from RNA polymerase II promoter in response to endoplasmic reticulum stress / positive regulation of transcription from RNA polymerase II promoter in response to hypoxia / positive regulation of transcription, DNA-templated / programmed cell death / protein complex assembly / protein import into nucleus, translocation / protein localization / protein tetramerization / Ras protein signal transduction / regulation of apoptotic process / regulation of cellular senescence / regulation of fibroblast apoptotic process / regulation of glycolytic process by positive regulation of transcription from RNA polymerase II promoter / regulation of intrinsic apoptotic signaling pathway by p53 class mediator / regulation of mitochondrial membrane permeability / regulation of mitochondrial membrane permeability involved in apoptotic process / regulation of tissue remodeling / regulation of transcription, DNA-templated / release of cytochrome c from mitochondria / replicative senescence / response to antibiotic / response to gamma radiation / response to ischemia / response to salt stress / response to X-ray / rRNA transcription / somitogenesis / T cell differentiation in thymus / T cell lineage commitment / T cell proliferation involved in immune response / transcription initiation from RNA polymerase II promoter / transforming growth factor beta receptor signaling pathway / viral process
Components
cytoplasm / cytosol / endoplasmic reticulum / mitochondrial matrix / mitochondrion / nuclear chromatin / nuclear matrix / nucleolus / nucleoplasm / nucleus / PML body / protein complex / replication fork
General Function
Not Available
Specific Function
Not Available
Pfam Domain Function
Transmembrane Regions
Not Available
Cellular Location
Cytoplasm
Gene sequence
>lcl|BSEQ0021858|Cellular tumor antigen p53 (TP53)
ATGGAGGAGCCGCAGTCAGATCCTAGCGTCGAGCCCCCTCTGAGTCAGGAAACATTTTCA
GACCTATGGAAACTACTTCCTGAAAACAACGTTCTGTCCCCCTTGCCGTCCCAAGCAATG
GATGATTTGATGCTGTCCCCGGACGATATTGAACAATGGTTCACTGAAGACCCAGGTCCA
GATGAAGCTCCCAGAATGCCAGAGGCTGCTCCCCCCGTGGCCCCTGCACCAGCAGCTCCT
ACACCGGCGGCCCCTGCACCAGCCCCCTCCTGGCCCCTGTCATCTTCTGTCCCTTCCCAG
AAAACCTACCAGGGCAGCTACGGTTTCCGTCTGGGCTTCTTGCATTCTGGGACAGCCAAG
TCTGTGACTTGCACGTACTCCCCTGCCCTCAACAAGATGTTTTGCCAACTGGCCAAGACC
TGCCCTGTGCAGCTGTGGGTTGATTCCACACCCCCGCCCGGCACCCGCGTCCGCGCCATG
GCCATCTACAAGCAGTCACAGCACATGACGGAGGTTGTGAGGCGCTGCCCCCACCATGAG
CGCTGCTCAGATAGCGATGGTCTGGCCCCTCCTCAGCATCTTATCCGAGTGGAAGGAAAT
TTGCGTGTGGAGTATTTGGATGACAGAAACACTTTTCGACATAGTGTGGTGGTGCCCTAT
GAGCCGCCTGAGGTTGGCTCTGACTGTACCACCATCCACTACAACTACATGTGTAACAGT
TCCTGCATGGGCGGCATGAACCGGAGGCCCATCCTCACCATCATCACACTGGAAGACTCC
AGTGGTAATCTACTGGGACGGAACAGCTTTGAGGTGCGTGTTTGTGCCTGTCCTGGGAGA
GACCGGCGCACAGAGGAAGAGAATCTCCGCAAGAAAGGGGAGCCTCACCACGAGCTGCCC
CCAGGGAGCACTAAGCGAGCACTGCCCAACAACACCAGCTCCTCTCCCCAGCCAAAGAAG
AAACCACTGGATGGAGAATATTTCACCCTTCAGATCCGTGGGCGTGAGCGCTTCGAGATG
TTCCGAGAGCTGAATGAGGCCTTGGAACTCAAGGATGCCCAGGCTGGGAAGGAGCCAGGG
GGGAGCAGGGCTCACTCCAGCCACCTGAAGTCCAAAAAGGGTCAGTCTACCTCCCGCCAT
AAAAAACTCATGTTCAAGACAGAAGGGCCTGACTCAGACTGA
Chromosome Location
Not Available
Locus
17p13.1
External Identifiers
ResourceLink
UniProtKB IDP04637
UniProtKB Entry NameP53_HUMAN
GenBank Gene IDX02469
GenAtlas IDTP53
HGNC IDHGNC:11998
General References
  1. Zakut-Houri R, Bienz-Tadmor B, Givol D, Oren M: Human p53 cellular tumor antigen: cDNA sequence and expression in COS cells. EMBO J. 1985 May;4(5):1251-5. [Article]
  2. Lamb P, Crawford L: Characterization of the human p53 gene. Mol Cell Biol. 1986 May;6(5):1379-85. [Article]
  3. Harlow E, Williamson NM, Ralston R, Helfman DM, Adams TE: Molecular cloning and in vitro expression of a cDNA clone for human cellular tumor antigen p53. Mol Cell Biol. 1985 Jul;5(7):1601-10. [Article]
  4. Harris N, Brill E, Shohat O, Prokocimer M, Wolf D, Arai N, Rotter V: Molecular basis for heterogeneity of the human p53 protein. Mol Cell Biol. 1986 Dec;6(12):4650-6. [Article]
  5. Buchman VL, Chumakov PM, Ninkina NN, Samarina OP, Georgiev GP: A variation in the structure of the protein-coding region of the human p53 gene. Gene. 1988 Oct 30;70(2):245-52. [Article]
  6. Farrell PJ, Allan GJ, Shanahan F, Vousden KH, Crook T: p53 is frequently mutated in Burkitt's lymphoma cell lines. EMBO J. 1991 Oct;10(10):2879-87. [Article]
  7. Allalunis-Turner MJ, Barron GM, Day RS 3rd, Dobler KD, Mirzayans R: Isolation of two cell lines from a human malignant glioma specimen differing in sensitivity to radiation and chemotherapeutic drugs. Radiat Res. 1993 Jun;134(3):349-54. [Article]
  8. Chang NS, Pratt N, Heath J, Schultz L, Sleve D, Carey GB, Zevotek N: Hyaluronidase induction of a WW domain-containing oxidoreductase that enhances tumor necrosis factor cytotoxicity. J Biol Chem. 2001 Feb 2;276(5):3361-70. Epub 2000 Oct 31. [Article]
  9. Bourdon JC, Fernandes K, Murray-Zmijewski F, Liu G, Diot A, Xirodimas DP, Saville MK, Lane DP: p53 isoforms can regulate p53 transcriptional activity. Genes Dev. 2005 Sep 15;19(18):2122-37. Epub 2005 Aug 30. [Article]
  10. Anderson CW, Allalunis-Turner MJ: Human TP53 from the malignant glioma-derived cell lines M059J and M059K has a cancer-associated mutation in exon 8. Radiat Res. 2000 Oct;154(4):473-6. [Article]
  11. Ota T, Suzuki Y, Nishikawa T, Otsuki T, Sugiyama T, Irie R, Wakamatsu A, Hayashi K, Sato H, Nagai K, Kimura K, Makita H, Sekine M, Obayashi M, Nishi T, Shibahara T, Tanaka T, Ishii S, Yamamoto J, Saito K, Kawai Y, Isono Y, Nakamura Y, Nagahari K, Murakami K, Yasuda T, Iwayanagi T, Wagatsuma M, Shiratori A, Sudo H, Hosoiri T, Kaku Y, Kodaira H, Kondo H, Sugawara M, Takahashi M, Kanda K, Yokoi T, Furuya T, Kikkawa E, Omura Y, Abe K, Kamihara K, Katsuta N, Sato K, Tanikawa M, Yamazaki M, Ninomiya K, Ishibashi T, Yamashita H, Murakawa K, Fujimori K, Tanai H, Kimata M, Watanabe M, Hiraoka S, Chiba Y, Ishida S, Ono Y, Takiguchi S, Watanabe S, Yosida M, Hotuta T, Kusano J, Kanehori K, Takahashi-Fujii A, Hara H, Tanase TO, Nomura Y, Togiya S, Komai F, Hara R, Takeuchi K, Arita M, Imose N, Musashino K, Yuuki H, Oshima A, Sasaki N, Aotsuka S, Yoshikawa Y, Matsunawa H, Ichihara T, Shiohata N, Sano S, Moriya S, Momiyama H, Satoh N, Takami S, Terashima Y, Suzuki O, Nakagawa S, Senoh A, Mizoguchi H, Goto Y, Shimizu F, Wakebe H, Hishigaki H, Watanabe T, Sugiyama A, Takemoto M, Kawakami B, Yamazaki M, Watanabe K, Kumagai A, Itakura S, Fukuzumi Y, Fujimori Y, Komiyama M, Tashiro H, Tanigami A, Fujiwara T, Ono T, Yamada K, Fujii Y, Ozaki K, Hirao M, Ohmori Y, Kawabata A, Hikiji T, Kobatake N, Inagaki H, Ikema Y, Okamoto S, Okitani R, Kawakami T, Noguchi S, Itoh T, Shigeta K, Senba T, Matsumura K, Nakajima Y, Mizuno T, Morinaga M, Sasaki M, Togashi T, Oyama M, Hata H, Watanabe M, Komatsu T, Mizushima-Sugano J, Satoh T, Shirai Y, Takahashi Y, Nakagawa K, Okumura K, Nagase T, Nomura N, Kikuchi H, Masuho Y, Yamashita R, Nakai K, Yada T, Nakamura Y, Ohara O, Isogai T, Sugano S: Complete sequencing and characterization of 21,243 full-length human cDNAs. Nat Genet. 2004 Jan;36(1):40-5. Epub 2003 Dec 21. [Article]
  12. Zody MC, Garber M, Adams DJ, Sharpe T, Harrow J, Lupski JR, Nicholson C, Searle SM, Wilming L, Young SK, Abouelleil A, Allen NR, Bi W, Bloom T, Borowsky ML, Bugalter BE, Butler J, Chang JL, Chen CK, Cook A, Corum B, Cuomo CA, de Jong PJ, DeCaprio D, Dewar K, FitzGerald M, Gilbert J, Gibson R, Gnerre S, Goldstein S, Grafham DV, Grocock R, Hafez N, Hagopian DS, Hart E, Norman CH, Humphray S, Jaffe DB, Jones M, Kamal M, Khodiyar VK, LaButti K, Laird G, Lehoczky J, Liu X, Lokyitsang T, Loveland J, Lui A, Macdonald P, Major JE, Matthews L, Mauceli E, McCarroll SA, Mihalev AH, Mudge J, Nguyen C, Nicol R, O'Leary SB, Osoegawa K, Schwartz DC, Shaw-Smith C, Stankiewicz P, Steward C, Swarbreck D, Venkataraman V, Whittaker CA, Yang X, Zimmer AR, Bradley A, Hubbard T, Birren BW, Rogers J, Lander ES, Nusbaum C: DNA sequence of human chromosome 17 and analysis of rearrangement in the human lineage. Nature. 2006 Apr 20;440(7087):1045-9. [Article]
  13. Gerhard DS, Wagner L, Feingold EA, Shenmen CM, Grouse LH, Schuler G, Klein SL, Old S, Rasooly R, Good P, Guyer M, Peck AM, Derge JG, Lipman D, Collins FS, Jang W, Sherry S, Feolo M, Misquitta L, Lee E, Rotmistrovsky K, Greenhut SF, Schaefer CF, Buetow K, Bonner TI, Haussler D, Kent J, Kiekhaus M, Furey T, Brent M, Prange C, Schreiber K, Shapiro N, Bhat NK, Hopkins RF, Hsie F, Driscoll T, Soares MB, Casavant TL, Scheetz TE, Brown-stein MJ, Usdin TB, Toshiyuki S, Carninci P, Piao Y, Dudekula DB, Ko MS, Kawakami K, Suzuki Y, Sugano S, Gruber CE, Smith MR, Simmons B, Moore T, Waterman R, Johnson SL, Ruan Y, Wei CL, Mathavan S, Gunaratne PH, Wu J, Garcia AM, Hulyk SW, Fuh E, Yuan Y, Sneed A, Kowis C, Hodgson A, Muzny DM, McPherson J, Gibbs RA, Fahey J, Helton E, Ketteman M, Madan A, Rodrigues S, Sanchez A, Whiting M, Madari A, Young AC, Wetherby KD, Granite SJ, Kwong PN, Brinkley CP, Pearson RL, Bouffard GG, Blakesly RW, Green ED, Dickson MC, Rodriguez AC, Grimwood J, Schmutz J, Myers RM, Butterfield YS, Griffith M, Griffith OL, Krzywinski MI, Liao N, Morin R, Palmquist D, Petrescu AS, Skalska U, Smailus DE, Stott JM, Schnerch A, Schein JE, Jones SJ, Holt RA, Baross A, Marra MA, Clifton S, Makowski KA, Bosak S, Malek J: The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC). Genome Res. 2004 Oct;14(10B):2121-7. [Article]
  14. Kanashiro CA, Schally AV, Groot K, Armatis P, Bernardino AL, Varga JL: Inhibition of mutant p53 expression and growth of DMS-153 small cell lung carcinoma by antagonists of growth hormone-releasing hormone and bombesin. Proc Natl Acad Sci U S A. 2003 Dec 23;100(26):15836-41. Epub 2003 Dec 5. [Article]
  15. Matlashewski G, Lamb P, Pim D, Peacock J, Crawford L, Benchimol S: Isolation and characterization of a human p53 cDNA clone: expression of the human p53 gene. EMBO J. 1984 Dec 20;3(13):3257-62. [Article]
  16. Addison C, Jenkins JR, Sturzbecher HW: The p53 nuclear localisation signal is structurally linked to a p34cdc2 kinase motif. Oncogene. 1990 Mar;5(3):423-6. [Article]
  17. Bischoff JR, Friedman PN, Marshak DR, Prives C, Beach D: Human p53 is phosphorylated by p60-cdc2 and cyclin B-cdc2. Proc Natl Acad Sci U S A. 1990 Jun;87(12):4766-70. [Article]
  18. Samad A, Carroll RB: The tumor suppressor p53 is bound to RNA by a stable covalent linkage. Mol Cell Biol. 1991 Mar;11(3):1598-606. [Article]
  19. Scheidtmann KH, Mumby MC, Rundell K, Walter G: Dephosphorylation of simian virus 40 large-T antigen and p53 protein by protein phosphatase 2A: inhibition by small-t antigen. Mol Cell Biol. 1991 Apr;11(4):1996-2003. [Article]
  20. Flaman JM, Waridel F, Estreicher A, Vannier A, Limacher JM, Gilbert D, Iggo R, Frebourg T: The human tumour suppressor gene p53 is alternatively spliced in normal cells. Oncogene. 1996 Feb 15;12(4):813-8. [Article]
  21. Shaw P, Freeman J, Bovey R, Iggo R: Regulation of specific DNA binding by p53: evidence for a role for O-glycosylation and charged residues at the carboxy-terminus. Oncogene. 1996 Feb 15;12(4):921-30. [Article]
  22. Ko LJ, Shieh SY, Chen X, Jayaraman L, Tamai K, Taya Y, Prives C, Pan ZQ: p53 is phosphorylated by CDK7-cyclin H in a p36MAT1-dependent manner. Mol Cell Biol. 1997 Dec;17(12):7220-9. [Article]
  23. Schneider E, Montenarh M, Wagner P: Regulation of CAK kinase activity by p53. Oncogene. 1998 Nov 26;17(21):2733-41. [Article]
  24. Dumaz N, Milne DM, Meek DW: Protein kinase CK1 is a p53-threonine 18 kinase which requires prior phosphorylation of serine 15. FEBS Lett. 1999 Dec 17;463(3):312-6. [Article]
  25. Liang SH, Clarke MF: A bipartite nuclear localization signal is required for p53 nuclear import regulated by a carboxyl-terminal domain. J Biol Chem. 1999 Nov 12;274(46):32699-703. [Article]
  26. Chehab NH, Malikzay A, Stavridi ES, Halazonetis TD: Phosphorylation of Ser-20 mediates stabilization of human p53 in response to DNA damage. Proc Natl Acad Sci U S A. 1999 Nov 23;96(24):13777-82. [Article]
  27. Fang S, Jensen JP, Ludwig RL, Vousden KH, Weissman AM: Mdm2 is a RING finger-dependent ubiquitin protein ligase for itself and p53. J Biol Chem. 2000 Mar 24;275(12):8945-51. [Article]
  28. Abraham J, Kelly J, Thibault P, Benchimol S: Post-translational modification of p53 protein in response to ionizing radiation analyzed by mass spectrometry. J Mol Biol. 2000 Jan 28;295(4):853-64. [Article]
  29. Luciani MG, Hutchins JR, Zheleva D, Hupp TR: The C-terminal regulatory domain of p53 contains a functional docking site for cyclin A. J Mol Biol. 2000 Jul 14;300(3):503-18. [Article]
  30. Guo A, Salomoni P, Luo J, Shih A, Zhong S, Gu W, Pandolfi PP: The function of PML in p53-dependent apoptosis. Nat Cell Biol. 2000 Oct;2(10):730-6. [Article]
  31. Sandy P, Gostissa M, Fogal V, Cecco LD, Szalay K, Rooney RJ, Schneider C, Del Sal G: p53 is involved in the p120E4F-mediated growth arrest. Oncogene. 2000 Jan 13;19(2):188-99. [Article]
  32. Lopez-Borges S, Lazo PA: The human vaccinia-related kinase 1 (VRK1) phosphorylates threonine-18 within the mdm-2 binding site of the p53 tumour suppressor protein. Oncogene. 2000 Jul 27;19(32):3656-64. [Article]
  33. Hainaut P, Mann K: Zinc binding and redox control of p53 structure and function. Antioxid Redox Signal. 2001 Aug;3(4):611-23. [Article]
  34. Imamura K, Ogura T, Kishimoto A, Kaminishi M, Esumi H: Cell cycle regulation via p53 phosphorylation by a 5'-AMP activated protein kinase activator, 5-aminoimidazole- 4-carboxamide-1-beta-D-ribofuranoside, in a human hepatocellular carcinoma cell line. Biochem Biophys Res Commun. 2001 Sep 21;287(2):562-7. [Article]
  35. Vaziri H, Dessain SK, Ng Eaton E, Imai SI, Frye RA, Pandita TK, Guarente L, Weinberg RA: hSIR2(SIRT1) functions as an NAD-dependent p53 deacetylase. Cell. 2001 Oct 19;107(2):149-59. [Article]
  36. Hong TM, Chen JJ, Peck K, Yang PC, Wu CW: p53 amino acids 339-346 represent the minimal p53 repression domain. J Biol Chem. 2001 Jan 12;276(2):1510-5. [Article]
  37. Xie S, Wang Q, Wu H, Cogswell J, Lu L, Jhanwar-Uniyal M, Dai W: Reactive oxygen species-induced phosphorylation of p53 on serine 20 is mediated in part by polo-like kinase-3. J Biol Chem. 2001 Sep 28;276(39):36194-9. Epub 2001 Jul 10. [Article]
  38. Xie S, Wu H, Wang Q, Cogswell JP, Husain I, Conn C, Stambrook P, Jhanwar-Uniyal M, Dai W: Plk3 functionally links DNA damage to cell cycle arrest and apoptosis at least in part via the p53 pathway. J Biol Chem. 2001 Nov 16;276(46):43305-12. Epub 2001 Sep 10. [Article]
  39. Rodriguez MS, Dargemont C, Hay RT: SUMO-1 conjugation in vivo requires both a consensus modification motif and nuclear targeting. J Biol Chem. 2001 Apr 20;276(16):12654-9. Epub 2000 Dec 21. [Article]
  40. Abe Y, Matsumoto S, Wei S, Nezu K, Miyoshi A, Kito K, Ueda N, Shigemoto K, Hitsumoto Y, Nikawa J, Enomoto Y: Cloning and characterization of a p53-related protein kinase expressed in interleukin-2-activated cytotoxic T-cells, epithelial tumor cell lines, and the testes. J Biol Chem. 2001 Nov 23;276(47):44003-11. Epub 2001 Sep 6. [Article]
  41. Keller DM, Zeng X, Wang Y, Zhang QH, Kapoor M, Shu H, Goodman R, Lozano G, Zhao Y, Lu H: A DNA damage-induced p53 serine 392 kinase complex contains CK2, hSpt16, and SSRP1. Mol Cell. 2001 Feb;7(2):283-92. [Article]
  42. Hu M, Li P, Li M, Li W, Yao T, Wu JW, Gu W, Cohen RE, Shi Y: Crystal structure of a UBP-family deubiquitinating enzyme in isolation and in complex with ubiquitin aldehyde. Cell. 2002 Dec 27;111(7):1041-54. [Article]
  43. Tsuji K, Mizumoto K, Yamochi T, Nishimoto I, Matsuoka M: Differential effect of ik3-1/cables on p53- and p73-induced cell death. J Biol Chem. 2002 Jan 25;277(4):2951-7. Epub 2001 Nov 12. [Article]
  44. Kim EJ, Park JS, Um SJ: Identification and characterization of HIPK2 interacting with p73 and modulating functions of the p53 family in vivo. J Biol Chem. 2002 Aug 30;277(35):32020-8. Epub 2002 Mar 29. [Article]
  45. Hofmann TG, Moller A, Sirma H, Zentgraf H, Taya Y, Droge W, Will H, Schmitz ML: Regulation of p53 activity by its interaction with homeodomain-interacting protein kinase-2. Nat Cell Biol. 2002 Jan;4(1):1-10. [Article]
  46. D'Orazi G, Cecchinelli B, Bruno T, Manni I, Higashimoto Y, Saito S, Gostissa M, Coen S, Marchetti A, Del Sal G, Piaggio G, Fanciulli M, Appella E, Soddu S: Homeodomain-interacting protein kinase-2 phosphorylates p53 at Ser 46 and mediates apoptosis. Nat Cell Biol. 2002 Jan;4(1):11-9. [Article]
  47. Shiseki M, Nagashima M, Pedeux RM, Kitahama-Shiseki M, Miura K, Okamura S, Onogi H, Higashimoto Y, Appella E, Yokota J, Harris CC: p29ING4 and p28ING5 bind to p53 and p300, and enhance p53 activity. Cancer Res. 2003 May 15;63(10):2373-8. [Article]
  48. Wang YH, Tsay YG, Tan BC, Lo WY, Lee SC: Identification and characterization of a novel p300-mediated p53 acetylation site, lysine 305. J Biol Chem. 2003 Jul 11;278(28):25568-76. Epub 2003 Apr 30. [Article]
  49. Louria-Hayon I, Grossman T, Sionov RV, Alsheich O, Pandolfi PP, Haupt Y: The promyelocytic leukemia protein protects p53 from Mdm2-mediated inhibition and degradation. J Biol Chem. 2003 Aug 29;278(35):33134-41. Epub 2003 Jun 16. [Article]
  50. Tomasini R, Samir AA, Carrier A, Isnardon D, Cecchinelli B, Soddu S, Malissen B, Dagorn JC, Iovanna JL, Dusetti NJ: TP53INP1s and homeodomain-interacting protein kinase-2 (HIPK2) are partners in regulating p53 activity. J Biol Chem. 2003 Sep 26;278(39):37722-9. Epub 2003 Jul 7. [Article]
  51. O'Keefe K, Li H, Zhang Y: Nucleocytoplasmic shuttling of p53 is essential for MDM2-mediated cytoplasmic degradation but not ubiquitination. Mol Cell Biol. 2003 Sep;23(18):6396-405. [Article]
  52. Kondo S, Lu Y, Debbas M, Lin AW, Sarosi I, Itie A, Wakeham A, Tuan J, Saris C, Elliott G, Ma W, Benchimol S, Lowe SW, Mak TW, Thukral SK: Characterization of cells and gene-targeted mice deficient for the p53-binding kinase homeodomain-interacting protein kinase 1 (HIPK1). Proc Natl Acad Sci U S A. 2003 Apr 29;100(9):5431-6. Epub 2003 Apr 17. [Article]
  53. Hasan MK, Yaguchi T, Minoda Y, Hirano T, Taira K, Wadhwa R, Kaul SC: Alternative reading frame protein (ARF)-independent function of CARF (collaborator of ARF) involves its interactions with p53: evidence for a novel p53-activation pathway and its negative feedback control. Biochem J. 2004 Jun 15;380(Pt 3):605-10. [Article]
  54. An W, Kim J, Roeder RG: Ordered cooperative functions of PRMT1, p300, and CARM1 in transcriptional activation by p53. Cell. 2004 Jun 11;117(6):735-48. [Article]
  55. Kojic S, Medeot E, Guccione E, Krmac H, Zara I, Martinelli V, Valle G, Faulkner G: The Ankrd2 protein, a link between the sarcomere and the nucleus in skeletal muscle. J Mol Biol. 2004 May 28;339(2):313-25. [Article]
  56. Li HH, Li AG, Sheppard HM, Liu X: Phosphorylation on Thr-55 by TAF1 mediates degradation of p53: a role for TAF1 in cell G1 progression. Mol Cell. 2004 Mar 26;13(6):867-78. [Article]
  57. Li M, Brooks CL, Kon N, Gu W: A dynamic role of HAUSP in the p53-Mdm2 pathway. Mol Cell. 2004 Mar 26;13(6):879-86. [Article]
  58. Ghosh A, Stewart D, Matlashewski G: Regulation of human p53 activity and cell localization by alternative splicing. Mol Cell Biol. 2004 Sep;24(18):7987-97. [Article]
  59. Chuikov S, Kurash JK, Wilson JR, Xiao B, Justin N, Ivanov GS, McKinney K, Tempst P, Prives C, Gamblin SJ, Barlev NA, Reinberg D: Regulation of p53 activity through lysine methylation. Nature. 2004 Nov 18;432(7015):353-60. Epub 2004 Nov 3. [Article]
  60. Katayama H, Sasai K, Kawai H, Yuan ZM, Bondaruk J, Suzuki F, Fujii S, Arlinghaus RB, Czerniak BA, Sen S: Phosphorylation by aurora kinase A induces Mdm2-mediated destabilization and inhibition of p53. Nat Genet. 2004 Jan;36(1):55-62. Epub 2003 Dec 14. [Article]
  61. Hublitz P, Kunowska N, Mayer UP, Muller JM, Heyne K, Yin N, Fritzsche C, Poli C, Miguet L, Schupp IW, van Grunsven LA, Potiers N, van Dorsselaer A, Metzger E, Roemer K, Schule R: NIR is a novel INHAT repressor that modulates the transcriptional activity of p53. Genes Dev. 2005 Dec 1;19(23):2912-24. [Article]
  62. Jalota A, Singh K, Pavithra L, Kaul-Ghanekar R, Jameel S, Chattopadhyay S: Tumor suppressor SMAR1 activates and stabilizes p53 through its arginine-serine-rich motif. J Biol Chem. 2005 Apr 22;280(16):16019-29. Epub 2005 Feb 8. [Article]
  63. Golubovskaya VM, Finch R, Cance WG: Direct interaction of the N-terminal domain of focal adhesion kinase with the N-terminal transactivation domain of p53. J Biol Chem. 2005 Jul 1;280(26):25008-21. Epub 2005 Apr 25. [Article]
  64. Chang NS, Doherty J, Ensign A, Schultz L, Hsu LJ, Hong Q: WOX1 is essential for tumor necrosis factor-, UV light-, staurosporine-, and p53-mediated cell death, and its tyrosine 33-phosphorylated form binds and stabilizes serine 46-phosphorylated p53. J Biol Chem. 2005 Dec 30;280(52):43100-8. Epub 2005 Oct 11. [Article]
  65. Jones RG, Plas DR, Kubek S, Buzzai M, Mu J, Xu Y, Birnbaum MJ, Thompson CB: AMP-activated protein kinase induces a p53-dependent metabolic checkpoint. Mol Cell. 2005 Apr 29;18(3):283-93. [Article]
  66. Zeng PY, Berger SL: LKB1 is recruited to the p21/WAF1 promoter by p53 to mediate transcriptional activation. Cancer Res. 2006 Nov 15;66(22):10701-8. [Article]
  67. Blanco S, Klimcakova L, Vega FM, Lazo PA: The subcellular localization of vaccinia-related kinase-2 (VRK2) isoforms determines their different effect on p53 stability in tumour cell lines. FEBS J. 2006 Jun;273(11):2487-504. [Article]
  68. Gu YM, Jin YH, Choi JK, Baek KH, Yeo CY, Lee KY: Protein kinase A phosphorylates and regulates dimerization of 14-3-3 epsilon. FEBS Lett. 2006 Jan 9;580(1):305-10. Epub 2005 Dec 19. [Article]
  69. Yoshida K, Liu H, Miki Y: Protein kinase C delta regulates Ser46 phosphorylation of p53 tumor suppressor in the apoptotic response to DNA damage. J Biol Chem. 2006 Mar 3;281(9):5734-40. Epub 2005 Dec 23. [Article]
  70. Huang J, Perez-Burgos L, Placek BJ, Sengupta R, Richter M, Dorsey JA, Kubicek S, Opravil S, Jenuwein T, Berger SL: Repression of p53 activity by Smyd2-mediated methylation. Nature. 2006 Nov 30;444(7119):629-32. Epub 2006 Nov 15. [Article]
  71. Tang J, Qu LK, Zhang J, Wang W, Michaelson JS, Degenhardt YY, El-Deiry WS, Yang X: Critical role for Daxx in regulating Mdm2. Nat Cell Biol. 2006 Aug;8(8):855-62. Epub 2006 Jul 16. [Article]
  72. Couture JF, Collazo E, Hauk G, Trievel RC: Structural basis for the methylation site specificity of SET7/9. Nat Struct Mol Biol. 2006 Feb;13(2):140-6. Epub 2006 Jan 15. [Article]
  73. Sun P, Yoshizuka N, New L, Moser BA, Li Y, Liao R, Xie C, Chen J, Deng Q, Yamout M, Dong MQ, Frangou CG, Yates JR 3rd, Wright PE, Han J: PRAK is essential for ras-induced senescence and tumor suppression. Cell. 2007 Jan 26;128(2):295-308. [Article]
  74. Das S, Raj L, Zhao B, Kimura Y, Bernstein A, Aaronson SA, Lee SW: Hzf Determines cell survival upon genotoxic stress by modulating p53 transactivation. Cell. 2007 Aug 24;130(4):624-37. [Article]
  75. Yamasaki S, Yagishita N, Sasaki T, Nakazawa M, Kato Y, Yamadera T, Bae E, Toriyama S, Ikeda R, Zhang L, Fujitani K, Yoo E, Tsuchimochi K, Ohta T, Araya N, Fujita H, Aratani S, Eguchi K, Komiya S, Maruyama I, Higashi N, Sato M, Senoo H, Ochi T, Yokoyama S, Amano T, Kim J, Gay S, Fukamizu A, Nishioka K, Tanaka K, Nakajima T: Cytoplasmic destruction of p53 by the endoplasmic reticulum-resident ubiquitin ligase 'Synoviolin'. EMBO J. 2007 Jan 10;26(1):113-22. Epub 2006 Dec 14. [Article]
  76. Li HH, Cai X, Shouse GP, Piluso LG, Liu X: A specific PP2A regulatory subunit, B56gamma, mediates DNA damage-induced dephosphorylation of p53 at Thr55. EMBO J. 2007 Jan 24;26(2):402-11. [Article]
  77. Zhou X, Yang G, Huang R, Chen X, Hu G: SVH-B interacts directly with p53 and suppresses the transcriptional activity of p53. FEBS Lett. 2007 Oct 16;581(25):4943-8. Epub 2007 Sep 21. [Article]
  78. Arai S, Matsushita A, Du K, Yagi K, Okazaki Y, Kurokawa R: Novel homeodomain-interacting protein kinase family member, HIPK4, phosphorylates human p53 at serine 9. FEBS Lett. 2007 Dec 11;581(29):5649-57. Epub 2007 Nov 20. [Article]
  79. Piskacek S, Gregor M, Nemethova M, Grabner M, Kovarik P, Piskacek M: Nine-amino-acid transactivation domain: establishment and prediction utilities. Genomics. 2007 Jun;89(6):756-68. Epub 2007 Apr 30. [Article]
  80. Yang W, Rozan LM, McDonald ER 3rd, Navaraj A, Liu JJ, Matthew EM, Wang W, Dicker DT, El-Deiry WS: CARPs are ubiquitin ligases that promote MDM2-independent p53 and phospho-p53ser20 degradation. J Biol Chem. 2007 Feb 2;282(5):3273-81. Epub 2006 Nov 22. [Article]
  81. Zhao Y, Katzman RB, Delmolino LM, Bhat I, Zhang Y, Gurumurthy CB, Germaniuk-Kurowska A, Reddi HV, Solomon A, Zeng MS, Kung A, Ma H, Gao Q, Dimri G, Stanculescu A, Miele L, Wu L, Griffin JD, Wazer DE, Band H, Band V: The notch regulator MAML1 interacts with p53 and functions as a coactivator. J Biol Chem. 2007 Apr 20;282(16):11969-81. Epub 2007 Feb 22. [Article]
  82. Lee JH, Kim HS, Lee SJ, Kim KT: Stabilization and activation of p53 induced by Cdk5 contributes to neuronal cell death. J Cell Sci. 2007 Jul 1;120(Pt 13):2259-71. [Article]
  83. Takahashi K, Yoshida N, Murakami N, Kawata K, Ishizaki H, Tanaka-Okamoto M, Miyoshi J, Zinn AR, Shime H, Inoue N: Dynamic regulation of p53 subnuclear localization and senescence by MORC3. Mol Biol Cell. 2007 May;18(5):1701-9. Epub 2007 Mar 1. [Article]
  84. Taira N, Nihira K, Yamaguchi T, Miki Y, Yoshida K: DYRK2 is targeted to the nucleus and controls p53 via Ser46 phosphorylation in the apoptotic response to DNA damage. Mol Cell. 2007 Mar 9;25(5):725-38. [Article]
  85. Huang J, Sengupta R, Espejo AB, Lee MG, Dorsey JA, Richter M, Opravil S, Shiekhattar R, Bedford MT, Jenuwein T, Berger SL: p53 is regulated by the lysine demethylase LSD1. Nature. 2007 Sep 6;449(7158):105-8. [Article]
  86. Shi X, Kachirskaia I, Yamaguchi H, West LE, Wen H, Wang EW, Dutta S, Appella E, Gozani O: Modulation of p53 function by SET8-mediated methylation at lysine 382. Mol Cell. 2007 Aug 17;27(4):636-46. [Article]
  87. Matsuoka S, Ballif BA, Smogorzewska A, McDonald ER 3rd, Hurov KE, Luo J, Bakalarski CE, Zhao Z, Solimini N, Lerenthal Y, Shiloh Y, Gygi SP, Elledge SJ: ATM and ATR substrate analysis reveals extensive protein networks responsive to DNA damage. Science. 2007 May 25;316(5828):1160-6. [Article]
  88. Jin YH, Kim YJ, Kim DW, Baek KH, Kang BY, Yeo CY, Lee KY: Sirt2 interacts with 14-3-3 beta/gamma and down-regulates the activity of p53. Biochem Biophys Res Commun. 2008 Apr 11;368(3):690-5. doi: 10.1016/j.bbrc.2008.01.114. Epub 2008 Feb 4. [Article]
  89. Xie P, Tian C, An L, Nie J, Lu K, Xing G, Zhang L, He F: Histone methyltransferase protein SETD2 interacts with p53 and selectively regulates its downstream genes. Cell Signal. 2008 Sep;20(9):1671-8. doi: 10.1016/j.cellsig.2008.05.012. Epub 2008 Jun 27. [Article]
  90. Lim ST, Chen XL, Lim Y, Hanson DA, Vo TT, Howerton K, Larocque N, Fisher SJ, Schlaepfer DD, Ilic D: Nuclear FAK promotes cell proliferation and survival through FERM-enhanced p53 degradation. Mol Cell. 2008 Jan 18;29(1):9-22. doi: 10.1016/j.molcel.2007.11.031. [Article]
  91. Shouse GP, Cai X, Liu X: Serine 15 phosphorylation of p53 directs its interaction with B56gamma and the tumor suppressor activity of B56gamma-specific protein phosphatase 2A. Mol Cell Biol. 2008 Jan;28(1):448-56. Epub 2007 Oct 29. [Article]
  92. Gauci S, Helbig AO, Slijper M, Krijgsveld J, Heck AJ, Mohammed S: Lys-N and trypsin cover complementary parts of the phosphoproteome in a refined SCX-based approach. Anal Chem. 2009 Jun 1;81(11):4493-501. doi: 10.1021/ac9004309. [Article]
  93. Lee EW, Lee MS, Camus S, Ghim J, Yang MR, Oh W, Ha NC, Lane DP, Song J: Differential regulation of p53 and p21 by MKRN1 E3 ligase controls cell cycle arrest and apoptosis. EMBO J. 2009 Jul 22;28(14):2100-13. doi: 10.1038/emboj.2009.164. Epub 2009 Jun 18. [Article]
  94. Yang X, Li H, Zhou Z, Wang WH, Deng A, Andrisani O, Liu X: Plk1-mediated phosphorylation of Topors regulates p53 stability. J Biol Chem. 2009 Jul 10;284(28):18588-92. doi: 10.1074/jbc.C109.001560. Epub 2009 May 27. [Article]
  95. Li DQ, Divijendra Natha Reddy S, Pakala SB, Wu X, Zhang Y, Rayala SK, Kumar R: MTA1 coregulator regulates p53 stability and function. J Biol Chem. 2009 Dec 11;284(50):34545-52. doi: 10.1074/jbc.M109.056499. Epub 2009 Oct 16. [Article]
  96. Hwang ES, Zhang Z, Cai H, Huang DY, Huong SM, Cha CY, Huang ES: Human cytomegalovirus IE1-72 protein interacts with p53 and inhibits p53-dependent transactivation by a mechanism different from that of IE2-86 protein. J Virol. 2009 Dec;83(23):12388-98. doi: 10.1128/JVI.00304-09. Epub 2009 Sep 23. [Article]
  97. Sun L, Shi L, Li W, Yu W, Liang J, Zhang H, Yang X, Wang Y, Li R, Yao X, Yi X, Shang Y: JFK, a Kelch domain-containing F-box protein, links the SCF complex to p53 regulation. Proc Natl Acad Sci U S A. 2009 Jun 23;106(25):10195-200. doi: 10.1073/pnas.0901864106. Epub 2009 Jun 9. [Article]
  98. Allton K, Jain AK, Herz HM, Tsai WW, Jung SY, Qin J, Bergmann A, Johnson RL, Barton MC: Trim24 targets endogenous p53 for degradation. Proc Natl Acad Sci U S A. 2009 Jul 14;106(28):11612-6. doi: 10.1073/pnas.0813177106. Epub 2009 Jun 25. [Article]
  99. Choudhary C, Kumar C, Gnad F, Nielsen ML, Rehman M, Walther TC, Olsen JV, Mann M: Lysine acetylation targets protein complexes and co-regulates major cellular functions. Science. 2009 Aug 14;325(5942):834-40. doi: 10.1126/science.1175371. Epub 2009 Jul 16. [Article]
  100. Yuan J, Luo K, Zhang L, Cheville JC, Lou Z: USP10 regulates p53 localization and stability by deubiquitinating p53. Cell. 2010 Feb 5;140(3):384-96. doi: 10.1016/j.cell.2009.12.032. Epub 2010 Jan 21. [Article]
  101. Huarte M, Guttman M, Feldser D, Garber M, Koziol MJ, Kenzelmann-Broz D, Khalil AM, Zuk O, Amit I, Rabani M, Attardi LD, Regev A, Lander ES, Jacks T, Rinn JL: A large intergenic noncoding RNA induced by p53 mediates global gene repression in the p53 response. Cell. 2010 Aug 6;142(3):409-19. doi: 10.1016/j.cell.2010.06.040. [Article]
  102. Venerando A, Marin O, Cozza G, Bustos VH, Sarno S, Pinna LA: Isoform specific phosphorylation of p53 by protein kinase CK1. Cell Mol Life Sci. 2010 Apr;67(7):1105-18. doi: 10.1007/s00018-009-0236-7. Epub 2009 Dec 30. [Article]
  103. Lim SO, Kim H, Jung G: p53 inhibits tumor cell invasion via the degradation of snail protein in hepatocellular carcinoma. FEBS Lett. 2010 Jun 3;584(11):2231-6. doi: 10.1016/j.febslet.2010.04.006. Epub 2010 Apr 10. [Article]
  104. Lim ST, Miller NL, Nam JO, Chen XL, Lim Y, Schlaepfer DD: Pyk2 inhibition of p53 as an adaptive and intrinsic mechanism facilitating cell proliferation and survival. J Biol Chem. 2010 Jan 15;285(3):1743-53. doi: 10.1074/jbc.M109.064212. Epub 2009 Oct 30. [Article]
  105. Huang J, Dorsey J, Chuikov S, Perez-Burgos L, Zhang X, Jenuwein T, Reinberg D, Berger SL: G9a and Glp methylate lysine 373 in the tumor suppressor p53. J Biol Chem. 2010 Mar 26;285(13):9636-41. doi: 10.1074/jbc.M109.062588. Epub 2010 Jan 29. [Article]
  106. Chen X, Zhu H, Yuan M, Fu J, Zhou Y, Ma L: G-protein-coupled receptor kinase 5 phosphorylates p53 and inhibits DNA damage-induced apoptosis. J Biol Chem. 2010 Apr 23;285(17):12823-30. doi: 10.1074/jbc.M109.094243. Epub 2010 Feb 2. [Article]
  107. Drost J, Mantovani F, Tocco F, Elkon R, Comel A, Holstege H, Kerkhoven R, Jonkers J, Voorhoeve PM, Agami R, Del Sal G: BRD7 is a candidate tumour suppressor gene required for p53 function. Nat Cell Biol. 2010 Apr;12(4):380-9. doi: 10.1038/ncb2038. Epub 2010 Mar 14. [Article]
  108. Fu X, Yucer N, Liu S, Li M, Yi P, Mu JJ, Yang T, Chu J, Jung SY, O'Malley BW, Gu W, Qin J, Wang Y: RFWD3-Mdm2 ubiquitin ligase complex positively regulates p53 stability in response to DNA damage. Proc Natl Acad Sci U S A. 2010 Mar 9;107(10):4579-84. doi: 10.1073/pnas.0912094107. Epub 2010 Feb 19. [Article]
  109. Burrows AE, Smogorzewska A, Elledge SJ: Polybromo-associated BRG1-associated factor components BRD7 and BAF180 are critical regulators of p53 required for induction of replicative senescence. Proc Natl Acad Sci U S A. 2010 Aug 10;107(32):14280-5. doi: 10.1073/pnas.1009559107. Epub 2010 Jul 26. [Article]
  110. Burkard TR, Planyavsky M, Kaupe I, Breitwieser FP, Burckstummer T, Bennett KL, Superti-Furga G, Colinge J: Initial characterization of the human central proteome. BMC Syst Biol. 2011 Jan 26;5:17. doi: 10.1186/1752-0509-5-17. [Article]
  111. Mori T, Ikeda DD, Fukushima T, Takenoshita S, Kochi H: NIRF constitutes a nodal point in the cell cycle network and is a candidate tumor suppressor. Cell Cycle. 2011 Oct 1;10(19):3284-99. doi: 10.4161/cc.10.19.17176. Epub 2011 Oct 1. [Article]
  112. Wu L, Ma CA, Zhao Y, Jain A: Aurora B interacts with NIR-p53, leading to p53 phosphorylation in its DNA-binding domain and subsequent functional suppression. J Biol Chem. 2011 Jan 21;286(3):2236-44. doi: 10.1074/jbc.M110.174755. Epub 2010 Oct 19. [Article]
  113. Stacey SN, Sulem P, Jonasdottir A, Masson G, Gudmundsson J, Gudbjartsson DF, Magnusson OT, Gudjonsson SA, Sigurgeirsson B, Thorisdottir K, Ragnarsson R, Benediktsdottir KR, Nexo BA, Tjonneland A, Overvad K, Rudnai P, Gurzau E, Koppova K, Hemminki K, Corredera C, Fuentelsaz V, Grasa P, Navarrete S, Fuertes F, Garcia-Prats MD, Sanambrosio E, Panadero A, De Juan A, Garcia A, Rivera F, Planelles D, Soriano V, Requena C, Aben KK, van Rossum MM, Cremers RG, van Oort IM, van Spronsen DJ, Schalken JA, Peters WH, Helfand BT, Donovan JL, Hamdy FC, Badescu D, Codreanu O, Jinga M, Csiki IE, Constantinescu V, Badea P, Mates IN, Dinu DE, Constantin A, Mates D, Kristjansdottir S, Agnarsson BA, Jonsson E, Barkardottir RB, Einarsson GV, Sigurdsson F, Moller PH, Stefansson T, Valdimarsson T, Johannsson OT, Sigurdsson H, Jonsson T, Jonasson JG, Tryggvadottir L, Rice T, Hansen HM, Xiao Y, Lachance DH, O Neill BP, Kosel ML, Decker PA, Thorleifsson G, Johannsdottir H, Helgadottir HT, Sigurdsson A, Steinthorsdottir V, Lindblom A, Sandler RS, Keku TO, Banasik K, Jorgensen T, Witte DR, Hansen T, Pedersen O, Jinga V, Neal DE, Catalona WJ, Wrensch M, Wiencke J, Jenkins RB, Nagore E, Vogel U, Kiemeney LA, Kumar R, Mayordomo JI, Olafsson JH, Kong A, Thorsteinsdottir U, Rafnar T, Stefansson K: A germline variant in the TP53 polyadenylation signal confers cancer susceptibility. Nat Genet. 2011 Sep 25;43(11):1098-103. doi: 10.1038/ng.926. [Article]
  114. Hou X, Liu JE, Liu W, Liu CY, Liu ZY, Sun ZY: A new role of NUAK1: directly phosphorylating p53 and regulating cell proliferation. Oncogene. 2011 Jun 30;30(26):2933-42. doi: 10.1038/onc.2011.19. Epub 2011 Feb 14. [Article]
  115. Vaseva AV, Marchenko ND, Ji K, Tsirka SE, Holzmann S, Moll UM: p53 opens the mitochondrial permeability transition pore to trigger necrosis. Cell. 2012 Jun 22;149(7):1536-48. doi: 10.1016/j.cell.2012.05.014. [Article]
  116. Bennett RL, Pan Y, Christian J, Hui T, May WS Jr: The RAX/PACT-PKR stress response pathway promotes p53 sumoylation and activation, leading to G(1) arrest. Cell Cycle. 2012 Jan 15;11(2):407-17. doi: 10.4161/cc.11.2.18999. Epub 2012 Jan 15. [Article]
  117. Iijima K, Yamada H, Miharu M, Imadome K, Miyagawa Y, Akimoto S, Kobayashi K, Okita H, Nakazawa A, Fujiwara S, Fujimoto J, Kiyokawa N: ZNF385B is characteristically expressed in germinal center B cells and involved in B-cell apoptosis. Eur J Immunol. 2012 Dec;42(12):3405-15. doi: 10.1002/eji.201242530. Epub 2012 Oct 16. [Article]
  118. Cui G, Park S, Badeaux AI, Kim D, Lee J, Thompson JR, Yan F, Kaneko S, Yuan Z, Botuyan MV, Bedford MT, Cheng JQ, Mer G: PHF20 is an effector protein of p53 double lysine methylation that stabilizes and activates p53. Nat Struct Mol Biol. 2012 Sep;19(9):916-24. doi: 10.1038/nsmb.2353. Epub 2012 Aug 5. [Article]
  119. Miki T, Matsumoto T, Zhao Z, Lee CC: p53 regulates Period2 expression and the circadian clock. Nat Commun. 2013;4:2444. doi: 10.1038/ncomms3444. [Article]
  120. Rokudai S, Laptenko O, Arnal SM, Taya Y, Kitabayashi I, Prives C: MOZ increases p53 acetylation and premature senescence through its complex formation with PML. Proc Natl Acad Sci U S A. 2013 Mar 5;110(10):3895-900. doi: 10.1073/pnas.1300490110. Epub 2013 Feb 19. [Article]
  121. Wimmer P, Berscheminski J, Blanchette P, Groitl P, Branton PE, Hay RT, Dobner T, Schreiner S: PML isoforms IV and V contribute to adenovirus-mediated oncogenic transformation by functionally inhibiting the tumor-suppressor p53. Oncogene. 2016 Jan 7;35(1):69-82. doi: 10.1038/onc.2015.63. Epub 2015 Mar 16. [Article]
  122. Clore GM, Omichinski JG, Sakaguchi K, Zambrano N, Sakamoto H, Appella E, Gronenborn AM: High-resolution structure of the oligomerization domain of p53 by multidimensional NMR. Science. 1994 Jul 15;265(5170):386-91. [Article]
  123. Lee W, Harvey TS, Yin Y, Yau P, Litchfield D, Arrowsmith CH: Solution structure of the tetrameric minimum transforming domain of p53. Nat Struct Biol. 1994 Dec;1(12):877-90. [Article]
  124. McCoy M, Stavridi ES, Waterman JL, Wieczorek AM, Opella SJ, Halazonetis TD: Hydrophobic side-chain size is a determinant of the three-dimensional structure of the p53 oligomerization domain. EMBO J. 1997 Oct 15;16(20):6230-6. [Article]
  125. Cho Y, Gorina S, Jeffrey PD, Pavletich NP: Crystal structure of a p53 tumor suppressor-DNA complex: understanding tumorigenic mutations. Science. 1994 Jul 15;265(5170):346-55. [Article]
  126. Jeffrey PD, Gorina S, Pavletich NP: Crystal structure of the tetramerization domain of the p53 tumor suppressor at 1.7 angstroms. Science. 1995 Mar 10;267(5203):1498-502. [Article]
  127. Kussie PH, Gorina S, Marechal V, Elenbaas B, Moreau J, Levine AJ, Pavletich NP: Structure of the MDM2 oncoprotein bound to the p53 tumor suppressor transactivation domain. Science. 1996 Nov 8;274(5289):948-53. [Article]
  128. Gorina S, Pavletich NP: Structure of the p53 tumor suppressor bound to the ankyrin and SH3 domains of 53BP2. Science. 1996 Nov 8;274(5289):1001-5. [Article]
  129. Joerger AC, Allen MD, Fersht AR: Crystal structure of a superstable mutant of human p53 core domain. Insights into the mechanism of rescuing oncogenic mutations. J Biol Chem. 2004 Jan 9;279(2):1291-6. Epub 2003 Oct 8. [Article]
  130. Kitayner M, Rozenberg H, Kessler N, Rabinovich D, Shaulov L, Haran TE, Shakked Z: Structural basis of DNA recognition by p53 tetramers. Mol Cell. 2006 Jun 23;22(6):741-53. [Article]
  131. Sheng Y, Saridakis V, Sarkari F, Duan S, Wu T, Arrowsmith CH, Frappier L: Molecular recognition of p53 and MDM2 by USP7/HAUSP. Nat Struct Mol Biol. 2006 Mar;13(3):285-91. Epub 2006 Feb 12. [Article]
  132. Hu M, Gu L, Li M, Jeffrey PD, Gu W, Shi Y: Structural basis of competitive recognition of p53 and MDM2 by HAUSP/USP7: implications for the regulation of the p53-MDM2 pathway. PLoS Biol. 2006 Feb;4(2):e27. Epub 2006 Jan 17. [Article]
  133. West LE, Roy S, Lachmi-Weiner K, Hayashi R, Shi X, Appella E, Kutateladze TG, Gozani O: The MBT repeats of L3MBTL1 link SET8-mediated p53 methylation at lysine 382 to target gene repression. J Biol Chem. 2010 Nov 26;285(48):37725-32. doi: 10.1074/jbc.M110.139527. Epub 2010 Sep 24. [Article]
  134. Harris CC: p53: at the crossroads of molecular carcinogenesis and risk assessment. Science. 1993 Dec 24;262(5142):1980-1. [Article]
  135. Hollstein M, Sidransky D, Vogelstein B, Harris CC: p53 mutations in human cancers. Science. 1991 Jul 5;253(5015):49-53. [Article]
  136. De Vries EM, Ricke DO, De Vries TN, Hartmann A, Blaszyk H, Liao D, Soussi T, Kovach JS, Sommer SS: Database of mutations in the p53 and APC tumor suppressor genes designed to facilitate molecular epidemiological analyses. Hum Mutat. 1996;7(3):202-13. [Article]
  137. Joerger AC, Ang HC, Fersht AR: Structural basis for understanding oncogenic p53 mutations and designing rescue drugs. Proc Natl Acad Sci U S A. 2006 Oct 10;103(41):15056-61. Epub 2006 Oct 2. [Article]
  138. Tu C, Tan YH, Shaw G, Zhou Z, Bai Y, Luo R, Ji X: Impact of low-frequency hotspot mutation R282Q on the structure of p53 DNA-binding domain as revealed by crystallography at 1.54 angstroms resolution. Acta Crystallogr D Biol Crystallogr. 2008 May;64(Pt 5):471-7. doi: 10.1107/S0907444908003338. Epub 2008 Apr 19. [Article]
  139. Boeckler FM, Joerger AC, Jaggi G, Rutherford TJ, Veprintsev DB, Fersht AR: Targeted rescue of a destabilized mutant of p53 by an in silico screened drug. Proc Natl Acad Sci U S A. 2008 Jul 29;105(30):10360-5. doi: 10.1073/pnas.0805326105. Epub 2008 Jul 23. [Article]
  140. Suad O, Rozenberg H, Brosh R, Diskin-Posner Y, Kessler N, Shimon LJ, Frolow F, Liran A, Rotter V, Shakked Z: Structural basis of restoring sequence-specific DNA binding and transactivation to mutant p53 by suppressor mutations. J Mol Biol. 2009 Jan 9;385(1):249-65. doi: 10.1016/j.jmb.2008.10.063. Epub 2008 Oct 30. [Article]
  141. Khoo KH, Joerger AC, Freund SM, Fersht AR: Stabilising the DNA-binding domain of p53 by rational design of its hydrophobic core. Protein Eng Des Sel. 2009 Jul;22(7):421-30. doi: 10.1093/protein/gzp018. Epub 2009 Jun 10. [Article]
  142. Basse N, Kaar JL, Settanni G, Joerger AC, Rutherford TJ, Fersht AR: Toward the rational design of p53-stabilizing drugs: probing the surface of the oncogenic Y220C mutant. Chem Biol. 2010 Jan 29;17(1):46-56. doi: 10.1016/j.chembiol.2009.12.011. [Article]
  143. Kitayner M, Rozenberg H, Rohs R, Suad O, Rabinovich D, Honig B, Shakked Z: Diversity in DNA recognition by p53 revealed by crystal structures with Hoogsteen base pairs. Nat Struct Mol Biol. 2010 Apr;17(4):423-9. doi: 10.1038/nsmb.1800. Epub 2010 Apr 4. [Article]
  144. Olschwang S, Laurent-Puig P, Vassal A, Salmon RJ, Thomas G: Characterization of a frequent polymorphism in the coding sequence of the Tp53 gene in colonic cancer patients and a control population. Hum Genet. 1991 Feb;86(4):369-70. [Article]
  145. Law JC, Strong LC, Chidambaram A, Ferrell RE: A germ line mutation in exon 5 of the p53 gene in an extended cancer family. Cancer Res. 1991 Dec 1;51(23 Pt 1):6385-7. [Article]
  146. Malkin D, Li FP, Strong LC, Fraumeni JF Jr, Nelson CE, Kim DH, Kassel J, Gryka MA, Bischoff FZ, Tainsky MA, et al.: Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms. Science. 1990 Nov 30;250(4985):1233-8. [Article]
  147. Srivastava S, Zou ZQ, Pirollo K, Blattner W, Chang EH: Germ-line transmission of a mutated p53 gene in a cancer-prone family with Li-Fraumeni syndrome. Nature. 1990 Dec 20-27;348(6303):747-9. [Article]
  148. Felix CA, Nau MM, Takahashi T, Mitsudomi T, Chiba I, Poplack DG, Reaman GH, Cole DE, Letterio JJ, Whang-Peng J, et al.: Hereditary and acquired p53 gene mutations in childhood acute lymphoblastic leukemia. J Clin Invest. 1992 Feb;89(2):640-7. [Article]
  149. Malkin D, Jolly KW, Barbier N, Look AT, Friend SH, Gebhardt MC, Andersen TI, Borresen AL, Li FP, Garber J, et al.: Germline mutations of the p53 tumor-suppressor gene in children and young adults with second malignant neoplasms. N Engl J Med. 1992 May 14;326(20):1309-15. [Article]
  150. Bartek J, Iggo R, Gannon J, Lane DP: Genetic and immunochemical analysis of mutant p53 in human breast cancer cell lines. Oncogene. 1990 Jun;5(6):893-9. [Article]
  151. Rodrigues NR, Rowan A, Smith ME, Kerr IB, Bodmer WF, Gannon JV, Lane DP: p53 mutations in colorectal cancer. Proc Natl Acad Sci U S A. 1990 Oct;87(19):7555-9. [Article]
  152. Hollstein MC, Metcalf RA, Welsh JA, Montesano R, Harris CC: Frequent mutation of the p53 gene in human esophageal cancer. Proc Natl Acad Sci U S A. 1990 Dec;87(24):9958-61. [Article]
  153. Ishioka C, Sato T, Gamoh M, Suzuki T, Shibata H, Kanamaru R, Wakui A, Yamazaki T: Mutations of the P53 gene, including an intronic point mutation, in colorectal tumors. Biochem Biophys Res Commun. 1991 Jun 28;177(3):901-6. [Article]
  154. Casson AG, Mukhopadhyay T, Cleary KR, Ro JY, Levin B, Roth JA: p53 gene mutations in Barrett's epithelium and esophageal cancer. Cancer Res. 1991 Aug 15;51(16):4495-9. [Article]
  155. Hsu IC, Metcalf RA, Sun T, Welsh JA, Wang NJ, Harris CC: Mutational hotspot in the p53 gene in human hepatocellular carcinomas. Nature. 1991 Apr 4;350(6317):427-8. [Article]
  156. Bressac B, Kew M, Wands J, Ozturk M: Selective G to T mutations of p53 gene in hepatocellular carcinoma from southern Africa. Nature. 1991 Apr 4;350(6317):429-31. [Article]
  157. Somers KD, Merrick MA, Lopez ME, Incognito LS, Schechter GL, Casey G: Frequent p53 mutations in head and neck cancer. Cancer Res. 1992 Nov 1;52(21):5997-6000. [Article]
  158. Crook T, Vousden KH: Properties of p53 mutations detected in primary and secondary cervical cancers suggest mechanisms of metastasis and involvement of environmental carcinogens. EMBO J. 1992 Nov;11(11):3935-40. [Article]
  159. Sakai E, Rikimaru K, Ueda M, Matsumoto Y, Ishii N, Enomoto S, Yamamoto H, Tsuchida N: The p53 tumor-suppressor gene and ras oncogene mutations in oral squamous-cell carcinoma. Int J Cancer. 1992 Dec 2;52(6):867-72. [Article]
  160. Bhatia K, Gutierrez MI, Magrath IT: A novel mutation in the p53 gene in a Burkitt's lymphoma cell line. Hum Mol Genet. 1992 Jun;1(3):207-8. [Article]
  161. Duthu A, Debuire B, Romano J, Ehrhart JC, Fiscella M, May E, Appella E, May P: p53 mutations in Raji cells: characterization and localization relative to other Burkitt's lymphomas. Oncogene. 1992 Nov;7(11):2161-7. [Article]
  162. Sun Y, Hegamyer G, Cheng YJ, Hildesheim A, Chen JY, Chen IH, Cao Y, Yao KT, Colburn NH: An infrequent point mutation of the p53 gene in human nasopharyngeal carcinoma. Proc Natl Acad Sci U S A. 1992 Jul 15;89(14):6516-20. [Article]
  163. Caamano J, Zhang SY, Rosvold EA, Bauer B, Klein-Szanto AJ: p53 alterations in human squamous cell carcinomas and carcinoma cell lines. Am J Pathol. 1993 Apr;142(4):1131-9. [Article]
  164. Boyle JO, Hakim J, Koch W, van der Riet P, Hruban RH, Roa RA, Correo R, Eby YJ, Ruppert JM, Sidransky D: The incidence of p53 mutations increases with progression of head and neck cancer. Cancer Res. 1993 Oct 1;53(19):4477-80. [Article]
  165. Hamelin R, Jego N, Laurent-Puig P, Vidaud M, Thomas G: Efficient screening of p53 mutations by denaturing gradient gel electrophoresis in colorectal tumors. Oncogene. 1993 Aug;8(8):2213-20. [Article]
  166. Birch JM, Hartley AL, Tricker KJ, Prosser J, Condie A, Kelsey AM, Harris M, Jones PH, Binchy A, Crowther D, et al.: Prevalence and diversity of constitutional mutations in the p53 gene among 21 Li-Fraumeni families. Cancer Res. 1994 Mar 1;54(5):1298-304. [Article]
  167. Zhang W, Guo XY, Hu GY, Liu WB, Shay JW, Deisseroth AB: A temperature-sensitive mutant of human p53. EMBO J. 1994 Jun 1;13(11):2535-44. [Article]
  168. Frebourg T, Barbier N, Yan YX, Garber JE, Dreyfus M, Fraumeni J Jr, Li FP, Friend SH: Germ-line p53 mutations in 15 families with Li-Fraumeni syndrome. Am J Hum Genet. 1995 Mar;56(3):608-15. [Article]
  169. Eeles RA: Germline mutations in the TP53 gene. Cancer Surv. 1995;25:101-24. [Article]
  170. Varley JM, McGown G, Thorncroft M, Tricker KJ, Teare MD, Santibanez-Koref MF, Martin J, Birch JM, Evans DG: An extended Li-Fraumeni kindred with gastric carcinoma and a codon 175 mutation in TP53. J Med Genet. 1995 Dec;32(12):942-5. [Article]
  171. Audrezet MP, Robaszkiewicz M, Mercier B, Nousbaum JB, Hardy E, Bail JP, Volant A, Lozac'h P, Gouerou H, Ferec C: Molecular analysis of the TP53 gene in Barrett's adenocarcinoma. Hum Mutat. 1996;7(2):109-13. [Article]
  172. Guldberg P, Nedergaard T, Nielsen HJ, Olsen AC, Ahrenkiel V, Zeuthen J: Single-step DGGE-based mutation scanning of the p53 gene: application to genetic diagnosis of colorectal cancer. Hum Mutat. 1997;9(4):348-55. [Article]
  173. Miyaki M, Nishio J, Konishi M, Kikuchi-Yanoshita R, Tanaka K, Muraoka M, Nagato M, Chong JM, Koike M, Terada T, Kawahara Y, Fukutome A, Tomiyama J, Chuganji Y, Momoi M, Utsunomiya J: Drastic genetic instability of tumors and normal tissues in Turcot syndrome. Oncogene. 1997 Dec 4;15(23):2877-81. [Article]
  174. van Rensburg EJ, Engelbrecht S, van Heerden WF, Kotze MJ, Raubenheimer EJ: Detection of p53 gene mutations in oral squamous cell carcinomas of a black African population sample. Hum Mutat. 1998;11(1):39-44. [Article]
  175. Luca JW, Strong LC, Hansen MF: A germline missense mutation R337C in exon 10 of the human p53 gene. Hum Mutat. 1998;Suppl 1:S58-61. [Article]
  176. Guran S, Tunca Y, Imirzalioglu N: Hereditary TP53 codon 292 and somatic P16INK4A codon 94 mutations in a Li-Fraumeni syndrome family. Cancer Genet Cytogenet. 1999 Sep;113(2):145-51. [Article]
  177. Hainaut P, Hollstein M: p53 and human cancer: the first ten thousand mutations. Adv Cancer Res. 2000;77:81-137. [Article]
  178. Ribeiro RC, Sandrini F, Figueiredo B, Zambetti GP, Michalkiewicz E, Lafferty AR, DeLacerda L, Rabin M, Cadwell C, Sampaio G, Cat I, Stratakis CA, Sandrini R: An inherited p53 mutation that contributes in a tissue-specific manner to pediatric adrenal cortical carcinoma. Proc Natl Acad Sci U S A. 2001 Jul 31;98(16):9330-5. [Article]
  179. Rutherford J, Chu CE, Duddy PM, Charlton RS, Chumas P, Taylor GR, Lu X, Barnes DM, Camplejohn RS: Investigations on a clinically and functionally unusual and novel germline p53 mutation. Br J Cancer. 2002 May 20;86(10):1592-6. [Article]
  180. Sjoblom T, Jones S, Wood LD, Parsons DW, Lin J, Barber TD, Mandelker D, Leary RJ, Ptak J, Silliman N, Szabo S, Buckhaults P, Farrell C, Meeh P, Markowitz SD, Willis J, Dawson D, Willson JK, Gazdar AF, Hartigan J, Wu L, Liu C, Parmigiani G, Park BH, Bachman KE, Papadopoulos N, Vogelstein B, Kinzler KW, Velculescu VE: The consensus coding sequences of human breast and colorectal cancers. Science. 2006 Oct 13;314(5797):268-74. Epub 2006 Sep 7. [Article]
  181. Chanock SJ, Burdett L, Yeager M, Llaca V, Langerod A, Presswalla S, Kaaresen R, Strausberg RL, Gerhard DS, Kristensen V, Perou CM, Borresen-Dale AL: Somatic sequence alterations in twenty-one genes selected by expression profile analysis of breast carcinomas. Breast Cancer Res. 2007;9(1):R5. [Article]
  182. Petitjean A, Mathe E, Kato S, Ishioka C, Tavtigian SV, Hainaut P, Olivier M: Impact of mutant p53 functional properties on TP53 mutation patterns and tumor phenotype: lessons from recent developments in the IARC TP53 database. Hum Mutat. 2007 Jun;28(6):622-9. [Article]
  183. Qin B, Minter-Dykhouse K, Yu J, Zhang J, Liu T, Zhang H, Lee S, Kim J, Wang L, Lou Z: DBC1 functions as a tumor suppressor by regulating p53 stability. Cell Rep. 2015 Mar 3;10(8):1324-34. doi: 10.1016/j.celrep.2015.01.066. Epub 2015 Feb 26. [Article]

Drug Relations

Drug Relations
DrugBank IDNameDrug groupPharmacological action?ActionsDetails
DB05404AZD 3355investigationalunknownDetails
DB083631-(9-ethyl-9H-carbazol-3-yl)-N-methylmethanamineexperimentalunknownDetails
DB00945Acetylsalicylic acidapproved, vet_approvedunknowninducerDetails
DB01593Zincapproved, investigationalunknownDetails
DB03347Triethyl phosphateexperimentalunknownDetails
DB14487Zinc acetateapproved, investigationalunknownDetails
DB14533Zinc chlorideapproved, investigationalunknownchaperoneDetails
DB14548Zinc sulfate, unspecified formapproved, experimentalunknownchaperoneDetails